Varubi patents expiration

VARUBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(3 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists
Dec, 2022

(9 months ago)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(3 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(3 years from now)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(3 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Jan, 2029

(5 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Oct, 2029

(6 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(8 years from now)

Varubi is owned by Tersera.

Varubi contains Rolapitant Hydrochloride.

Varubi has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Varubi are:

  • US8796299

Varubi was authorised for market use on 01 September, 2015.

Varubi is available in tablet;oral dosage forms.

Varubi can be used as prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy.

The generics of Varubi are possible to be released after 14 July, 2032.

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2015

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy


More Information on Dosage

VARUBI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic